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Abstract Based on their bronchodilatory effect, β2-
adrenoceptor agonists constitute essential elements in the treat-
ment of bronchial asthma and COPD. As treatment with β2-
adrenoceptor agonists has been associated with worsening of
airway hyper-reactivity, possibly because of loss of β-
adrenoceptor function, molecular mechanism of the regulation
of β2-adrenoceptor expression were studied. MRC-5 human
lung fibroblasts were cultured in absence or presence of test
substances followed by β2-adrenoceptor messenger RNA
(mRNA) determination by qPCR. After inhibition of mRNA
synthesis by actinomycin D, β2-adrenoceptor mRNA decreased
with a half-life of 23min, whereas inhibition of protein synthesis
by cycloheximide caused an about 5- and 6-fold increase within
1.5 and 4 h, respectively. β2-Adrenoceptor mRNA was in-
creased by about 100 % after 1 h exposure to formoterol or
olodaterol but decreased by about 60 % after 4 h agonist
exposure. Both effects of β2-adrenoceptor agonists were mim-
icked by forskolin, a direct activator of adenylyl cyclase and
cholera toxin, which stimulates adenylyl cyclase by permanent
activation of Gs.β2-Adrenoceptor agonist-induced upregulation
ofβ2-adrenoceptor mRNAwas blocked by the β2-adrenoceptor
antagonist ICI 118551 and prevented by actinomycin D, but not
by cycloheximide. Moreover, in presence of cycloheximide,β2-
adrenoceptor agonist-induced reduction in β2-adrenoceptor
mRNAwas converted into stimulation, resulting in a more than
10-fold increase. In conclusion, expression of β2-adrenoceptors
in human lung fibroblasts is highly regulated at transcriptional
level. The β2-adrenoceptor gene is under strong inhibitory
control of short-living suppressor proteins. β2-Adrenoceptor
activation induces via adenylyl cyclase - cyclic adenosine
monophosphate (cAMP) signaling a rapid in onset direct stim-
ulation of the β2-adrenoceptor gene transcription, an effect
opposed by a delayed upregulation of inhibitory factors.
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Introduction
Based on their bronchodilatory effect, β2-adrenergic agonists
constitute an essential element in the treatment of bronchial
asthma and COPD (e.g., Sin et al. 2003; Barnes 2004; Walters
et al. 2005; Fitzgerald and Fox 2007; Cazzola et al. 2011).
However, there is increasing evidence that they may exert a
number of additional effects of potential therapeutic value. Thus,
we recently showed that human lung fibroblasts express β2-
adrenoceptors which mediate various inhibitory effects on pro-
fibrotic features (Lamyel et al. 2011). On the other hand, treat-
ment with long-acting β2-adrenoceptor agonists has been asso-
ciated with possible worsening of airway hyper-reactivity (e.g.,
Martinez 2005; Nelson 2006; Cockcroft 2006; Cazzola et al.
2011), possibly because of loss of β2-adrenoceptor function.
There is evidence for a complex agonist-mediated modulation
ofβ2-adrenoceptor responsiveness, involving effects effect at the
transcriptional and post-transcriptional levels. A large number of
studies documented downregulation of β2-adrenoceptor density
after prolonged agonist exposure, which involves several mech-
anisms, including downregulation ofβ2-adrenoceptor messenger
RNA (mRNA) (e.g., Bouvier et al. 1989; Hadcock et al. 1989;
Collins et al. 1989;Hosoda et al. 1995; Tittelbach et al. 1998). On
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the other hand, there is evidence that β-adrenoceptor agonist
exposure can via cAMP-signaling enhance β2-adrenoceptor
gene expression (Collins et al. 1989). However, substantial cell
specific differences in the regulation of β2-adrenoceptor mRNA
appear to be exist (Danner and Lohse 1997).
Therefore, the present study aimed to analyze molecular
mechanisms involved in the regulation of β2-adrenoceptor
expression in human lung fibroblasts, which have been
identified as a new target for drugs used in the treatment
of chronic obstructive airway diseases (Racké et al. 2008).
In particular, a potential time-dependent modulation of β2-
adrenoceptor mRNA expression by β2-adrenoceptor activa-
tion and the down-stream cAMP signaling pathway were
explored.
Preliminary reports of some of the data have been given
(Warnken-Uhlich et al. 2011, Kämpfer et al. 2012).
Materials and methods
Culture of lung fibroblasts
MCR-5 human lung fibroblasts (CCL-171, ATCC, Manassas,
USA) were grown in Eagle’s MEM supplemented with 10 %
FCS, 2mML-glutamine; Earle’s BBS adjusted to contain 2.2 g/l
sodium bicarbonate, 0.1 mM non-essential amino acids, 1.0 mM
sodium pyruvate, 100 U/ml penicillin, and 100 μg/ml strepto-
mycin. Cells were grown in a humidified incubator at 37 °C and
5 % CO2 and passaged by trypsinization at nearly confluence.
Extraction of RNA and real-time reverse
transcription-polymerase chain reaction
Total RNAwas isolated by help of silica-gel-based membranes
according to manufacturer’s instructions including an additional
DNase digestion protocol to beware any contamination by ge-
nomic DNA (Qiagen, Hilden, Germany). First strand cDNAwas
synthesized using Omniscript reverse transcriptase (Qiagen).
Quantitative PCR was performed by monitoring the fluo-
rescence of SYBR Green dye on a Statagene Mx3000P real-
time PCR system. Applied primer pairs (based on human
EMBL sequences) were specific for the β2-adrenoceptor 5′-
GATTTCAGGATTGCCTTCCAG-3′ and 5′GTGATATCCA
CTCTGCTCCCC-3′ and the housekeeping gene GAPDH, 5′-
CTGCACCACCAACTGCTTAGC-3′ and 5′-GGCATGGA
CTGTGGTCATGAG-3′ which were used for normalization.
The cycling conditions were the following: 10 min polymer-
ase activation at 95 °C and 40 cycles at 95 °C for 30 s, 59 °C
for 30 s, and 72 °C for 30 s. The threshold was automatically
set by the software. The crossing point of the amplification
curve with the threshold represents the “Ct.”
Fluorescence data from each sample were analyzed with
the 2−[ΔΔCt] method: fold induction=2−[ΔΔCt], where
ΔΔCt=[Ct GI (unknown sample)−Ct GAPDH (unknown
sample)]−[Ct GI (calibrator sample)−Ct GAPDH (calibrator
sample)], GI is the gene of interest.
Analysis of cellular cyclic AMP accumulation
Cellular cAMP levels were determined as described previous-
ly (Hoffmann et al., 2008). In brief, MRC-5 cells were cul-
tured on 24-well plates for 24 h. After removal of the culture
medium, cells were incubated with HBSS buffer at 36.5 °C for
2 h followed by additional 10min, 60min, or 4 h in absence or
presence of test substances or solvent control (DMSO). The
reaction was stopped by removal of the reaction buffer follow-
ed by the addition of a hot lysis solution (Na2EDTA 4 mM,
Triton X 100 0.01 %, pH 7.5). cAMP levels in the supernatant
were then quantified by incubation of an aliquot with cAMP-
binding protein and [3H] cAMP (Perkin Elmer, Boston, USA),
and liquid scintillation counting after removal of the unbound
cAMP by charcoal. cAMP levels per well were calculated by
regression analysis from a standard curve determined for each
experiment. cAMP levels were expressed either in absolute
values (pmol/500 μl) or as percent of the mean value observed
in presence of forskolin in each cell preparation.
Statistical analysis
All values are means with SEM of n experiments. Statistical
significance of differences was evaluated by ANOVA follow-
ed by Dunnett or Bonferroni test using GraphPad InStat
(GraphPad Software, San Diego, USA). P<0.05 was accepted
as significant.
Drugs and materials
Formoterol was a gift from AstraZeneca (Lund, Sweden) and
olodaterol from Boehringer Ingelheim (Biberach, Germany).
All other drugs were purchased: actinomycin D, cholera toxin,
cycloheximide, forskolin, isoprenaline, IBMX (2-isobutyl-1-
methylxanthine), orciprenaline, penicillin-streptomycin solu-
tion, and trypsin from Sigma (Deisenhofen, Germany); ICI
118,551 ((±)-1-[(2,3-dihydro-7-methyl-1H-inden-4-yl)oxy]-
3-[(1-methylethyl) amino]-2-butanol hydrochloride) from
Biozo l (Ech ing , Germany) ; 6 -Bnz -cAMP (N6-
benzyladenosine-3′,5′-phosphate) and 8-pCPT-2′–O-Me-
cAMP (8-(4-chlorophenylthio)-2′–O-methyladenosine-
cAMP) from Biolog Life Science Institute (Bremen, Germa-
ny); desoxynucleotide mixture from Fermentas (St. Leon-Rot,
Germany); Eagle’s minimal essential medium (MEM) with
Earl’s salts and L-glutamine, non-essential amino acids from
PAA (Cölbe, Germany); fetal calf serum (FCS) from
Biochrom (Berlin, Germany); Taq DNA-polymerase from
Invitrogen (Karlsruhe, Germany); and Omniscript reverse
transcriptase, RNeasy Mini kit, QuantiTectTM SYBR Green
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PCR kit, and RNase-free DNase set from Qiagen (Hilden,
Germany). Oligodesoxynucleotides for qPCR were obtained
from Eurofins MWG Operon (Ebersberg, Germany).
Results
By using quantitative real-time PCR, the present study con-
firms previous observations based on semi-quantitative RT-
PCR that human lung fibroblasts express significant amounts
of mRNA encoding β2-adrenoceptors. Under control condi-
tions, the β2-adrenoceptors mRNA levels, expressed as ΔCt
over GAPDH, amounted to 12.1±0.1 (n=60) and were very
similar in several series of experiments. After inhibition of de
novo RNA synthesis by actinomycin D, β2-adrenoceptor
mRNA showed a rapid decline, with a half-life of about
23 min (Fig. 1a). On the other hand, inhibition of protein
synthesis by cycloheximide resulted in rapid, marked increase
inβ2-adrenoceptor mRNA, about 5-fold within 1.5 h and only
slightly higher after 4 and 6 h (Fig. 1b). Actinomycin, present
10 min prior to cycloheximide, almost prevented the increase
induced by cycloheximide (Fig. 1c).
Exposure to β2-adrenoceptor agonists showed time-
dependent opposing effects on β2-adrenoceptor mRNA ex-
pression. As shown in Fig. 2 for formoterol, β2-adrenoceptor
agonist exposure resulted in a very rapid increase in β2-
adrenoceptor mRNA, significantly already after 20 min, and
a maximal increase by about 150 % was observed within 1 h.
This effect vanished after 2 h, and an inhibition by about 55 %
Fig. 1 Time-dependent effects of actinomycin D (Act, 30 μM) and/or
cycloheximide (CHX, 30 μM) on β2-adrenoceptor mRNA expression in
MRC-5 human lung fibroblasts. After dissemination, cells were cultured
for 24 h in presence of 10 % FCS followed by up to 24 h in FCS-free
medium in absence or presence of test drugs. When Act and CHX were
present together (c), Act was present 10 min before the addition of CHX
for further 90min. Thereafter, total RNAwas isolated, treated with DNase
and used for quantitative real-time PCR. Ordinate (a) and height of
columns (b, c): β2-adrenoceptor mRNA (−2ΔΔCt×100) is expressed as
percent of the respective control of the individual cell preparation, given
are means with SEM of n≥5. Significance of differences: *P<0.05;
**P<0.01; ***P<0.001 vs respective control; +++P<0.01 vs CHX
Fig. 2 Time-dependent effects of formoterol on β2-adrenoceptor mRNA
expression in MRC-5 human lung fibroblasts. After dissemination, cells
were cultured for 24 h in presence of 10 % FCS followed by up to 48 h in
FCS-free medium in absence or presence of formoterol (100 nM). There-
after, total RNAwas isolated, treated with DNase and used for quantita-
tive real-time PCR. Ordinate: β2-adrenoceptor mRNA (−2ΔΔCt×100) is
expressed as percent of the respective control of the individual cell
preparation, given are means±S.E.M. of n≥6. Significance of differ-
ences: **P<0.01 vs respective control
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was seen after 4 h, but also this effect was lost over time and
an enhanced expression was again seen after 48 h (Fig. 2).
Similar effects were also evoked by olodaterol, another long-
acting β2-adrenoceptor agonist (Bouyssou et al. 2010)
(Figs. 3a and 6) as well as by the short-acting agonists
isoprenaline and orciprenaline (data not shown). The stimu-
latory effects of the β2-adrenoceptor agonists were mimicked
by direct activation of adenylyl cyclase, either by exposure to
cholera toxin or to forskolin (Fig. 3b) and also by the
prostanoid (EP2) receptor agonist butaprost. The effects of
forskolin and butaprost were not additive to that of the β2-
adrenoceptor agonist olodaterol (Fig. 3b). Finally, the
selective β2-adrenoceptor antagonist ICI 118551 (Baker
2005) prevented the stimulatory (Fig. 4) as well as the
inhibitory (Fig. 6) effects of the β2-adrenoceptor agonists
but did not affect the upregulation caused by forskolin
(Fig. 4). After inhibition of de novo RNA synthesis by
actinomycin D, the stimulatory effect of formoterol was
abolished, whereas in presence of cycloheximide, which by
its own caused already a marked increase in β2-adrenoceptor
mRNA, formoterol elicited a further marked increase (Fig. 5),
resulting in an almost 9-fold increase when cycloheximide
and the β2-adrenoceptor agonist were concomitantly present.
The half-life of the β2-adrenoceptor mRNA in presence of
Fig. 3 Comparison of the concentration-dependent effects of formoterol
and olodaterol (a) and the effects of cholera toxin (CTX), forskolin (Fors),
butaprost (Buta), and olodaterol (Olod, 10 nM) (b) on β2-adrenoceptor
mRNA expression in MRC-5 human lung fibroblasts. After dissemina-
tion, cells were cultured for 24 h in presence of 10% FCS followed by 1 h
in FCS-free medium in absence or presence of test drugs at the
concentrations given. Thereafter, total RNA was isolated, treated with
DNase and used for quantitative real-time PCR. Height of columns: β2-
adrenoceptor mRNA (−2ΔΔCt×100) is expressed as percent of the re-
spective control of the individual cell preparation, given are means+SEM
of n≥6. Significance of differences: **P<0.01; ***P<0.001 vs respec-
tive control; not significant (ns) vs respective value in absence of Olod
Fig. 4 Effects formoterol (Formo, 100 nM), olodaterol (Olod, 10 nM),
forskolin (Fors, 10 μM), and/or ICI 118551 (ICI, 3 μM) on β2-
adrenoceptor mRNA expression inMRC-5 human lung fibroblasts. After
dissemination, cells were cultured for 24 h in presence of 10 % FCS
followed by 20 or 60 min in FCS-free medium in absence or presence of
test drugs at the concentrations given. Thereafter, total RNAwas isolated,
treated with DNase, and used for quantitative real-time PCR. Height of
columns: β2-adrenoceptor mRNA (−2ΔΔCt×100) is expressed as percent
of the respective control of the individual cell preparation, given are
means+SEM of n≥4. Significance of differences: **P<0.01;
***P<0.001 vs respective control; +P<0.05; ++P<0.01 vs respective
value in absence of ICI 118551; not significantly (ns) different vs respec-
tive value in absence of ICI 118551
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100 nM formoterol was about 26 min, i.e., it was not signif-
icantly affected by agonist exposure.
Cholera toxin, like forskolin, also mimicked the inhibitory
effect of the β2-adrenoceptor agonists on β2-adrenoceptor
receptor mRNA seen after a 4-h drug exposure (Fig. 6). Fi-
nally, the 4-h exposure to the phosphodiesterase inhibitor
IBMX also caused a reduction in β2-adrenoceptor receptor
mRNA by about 50 % (Fig. 6). However, it should be men-
tioned, that short-time exposure (1 h) to IBMX (1–100 μM)
did not significantly affect β2-adrenoceptor receptor mRNA
expression (data not shown). As already described above
(Fig. 1), inhibition of protein de novo synthesis by
cycloheximide resulted in marked increases in β2-
adrenoceptor mRNA levels. In presence of cycloheximide,
the inhibitory effect of olodaterol (4 h) was prevented and
converted into a marked stimulatory effect. Concomitant pres-
ence of cycloheximide and the β2-adrenoceptor agonist re-
sulted in an about 14-fold increase in β2-adrenoceptor recep-
tor mRNA levels (Fig. 6).
Exposure to the selective PKA agonist 6-Bnz-cAMP or the
selective Epac agonist 8-CPT-2′–O-Me-cAMP for 1 h (data
not shown) or 4 h (Fig. 7) did not significantly affect β2-
adrenoceptor mRNA levels. However, in presence of
cycloheximide, 6-Bnz-cAMP, but not 8-CPT-2′–O-Me-
Fig. 5 Effects of formoterol (a at the concentration given; b 100
nM) and/or actinomycin (30 μM) (a, c) or cycloheximide (CHX, 30 μM)
on β2-adrenoceptor mRNA expression in MRC-5 human lung fibro-
blasts. After dissemination, cells were cultured for 24 h in presence of
10% FCS followed by 1 h in FCS-free medium in absence or presence of
test drugs at the concentrations given, actinomycin D being present
10 min and CHX 30 min before formoterol. Thereafter, total RNA was
isolated, treated with DNase and used for quantitative real-time PCR.
Height of columns: β2-adrenoceptor mRNA (−2ΔΔCt×100) is expressed
as percent of the respective control of the individual cell preparation,
given are means+SEM of n≥6. Significance of differences: *P<0.05;
**P<0.01; ***P<0.001 vs respective control; +P<0.05 vs CHX alone;
not significant (ns) vs actinomycin alone
Fig. 6 Effects of formoterol (Formo, 10 nM), olodatereol (Olod, 10 nM),
cholera toxin (CTX, 5 ng/ml), forskolin (Fors, 10 µM) or IBMX (100 μM),
ICI 118551 (ICI, 3 μM) alone or in combination with Formo (left hand
scale), or cycloheximide (CHX, 30 μM) alone or in combination with Olod
(10 nM, right hand scale) on β2-adrenoceptor mRNA expression in MRC-
5 human lung fibroblasts. After dissemination, cells were cultured for 24 h
in presence of 10%FCS followed by 4 h in FCS-freemedium in absence or
presence of test drugs at the concentrations given, CHX being present
30min before Olod. Thereafter, total RNAwas isolated, treatedwith DNase
and used for quantitative real-time PCR. Height of columns: β2-
adrenoceptor mRNA (−2ΔΔCt * 100) is expressed as percent of the respec-
tive control of the individual cell preparation, given are means+SEM of n≥
6. Significance of differences: ***P<0.001 vs respective control;
+++P<0.01 vs CHX alone; ##P<0.01 vs Formo alone
Fig. 7 Effects of the selective PKA (6-Bnz-cAMP, 500 μM) or Epac (8-
CPT-2′–O-Me-cAMP, 100 μM) agonist (left hand scale) or cyclohexi-
mide (CHX, 30 μM) alone and in combination with the Epac or PKA
agonists (right hand scale) on β2-adrenoceptor mRNA expression in
MRC-5 human lung fibroblasts. After dissemination, cells were cultured
for 24 h in presence of 10 % FCS followed by 4 h in FCS-free medium in
absence or presence of test drugs at the concentrations given, CHX being
present 30 min before the Epac and PKA agonists. Thereafter, total RNA
was isolated, treated with DNase and used for quantitative real-time PCR.
Height of columns: β2-adrenoceptor mRNA (−2ΔΔCt×100) is expressed
as percent of the respective control of the individual cell preparation,
given are means+SEM of n≥6. Significance of differences: ***P<0.001
vs respective control; ++P<0.01 vs CHX alone
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cAMP, caused a significant further increase in β2-
adrenoceptor mRNA levels at 4 h (Fig. 7).
In further experiments, time-dependent effects of formoterol,
butaprost, forskolin, choleratoxin, and IBMX on cellular
cAMP were studied. In most experiments, basal cAMP levels
were below or very close to the detection limit. Formoterol,
butaprost, and forskolin induced a clear increase in cellular
cAMP already within 10 min (Fig. 8b). Forskolin caused the
strongest increase and cellular cAMP remained at the same level
for up to 2 h. After 4 h presence of forskolin, cellular cAMPwas
still clearly elevated but significantly lower compared to the
initial 10 min period (Fig. 8a). In the initial 10 min, the effect
of forskolin was compared to that of formoterol about 4-fold
and compared to butaprost about 2-fold larger (Fig. 8b), and
butaprost was significantly more effective than formoterol
(Fig. 8b). However, the difference between formoterol and
butaprost vanished with longer exposure times, as the effect
of butaprost diminished (Fig. 8c, d). A significant increase in
cellular cAMP was also induced by cholera toxin, but the rise
occurred with some delay; elevated cellular cAMP levels were
observed after 1 and 4 h, but not after 10 min. Surprisingly,
IBMX failed to induce a significant rise in cellular cAMP at all
time points studied. There was a tendency for a small increase
after 4 h, which however failed to be statistically significant.
Exposure for 1 or 2 h to cycloheximide (30 μM), which had
caused a marked upregulation of β2-adrenoceptor
mRNA within 1.5 h (Fig. 1), did not cause any increase in
cellular cAMP (data not shown, each n=8).
Discussion
As outlined in the Introduction, due to their bronchodilatatory
action,β-adrenoceptor agonists are an essential element in the
treatment of chronic obstructive airway diseases. However,
other cells, in addition to the airway smooth muscle, might be
an addditional target for β-adrenoceptor agonists. Thus, hu-
man lung fibroblasts express β2-adrenoceptors (Lamyel et al.
2011) which appear to inhibit pro-fibrotic features, such as
myo-fibroblast differentiation, proliferation, and collagen syn-
thesis (Liu et al. 2004; Lamyel et al. 2011). Since in chronic
obstructive airway disease, β-agonists are applied as long-
term treatment, the present study aimed to explore possible
agonist-induced changes in β2-adrenoceptor expression in
human lung fibroblasts.
Previous studies from our laboratory demonstrated that
MRC-5 and primary human lung fibroblasts showed verymuch
the same results with regard to the expression and functional
response of several G-protein-coupled receptors (Matthiesen
et al. 2006; Haag et al., 2008a, b; Ahmedat et al. 2010) and
so far studied signal transduction mechanisms (Haag et al.
2008b). Since in particular, MRC-5 and primary human lung
Fig. 8 Effects of forskolin (Fors, 10 μM), formoterol (Formo, 100 nM),
butaprost (Buta, 100 nM), cholera toxin (CTX, 5 ng/ml), or IBMX
(100 μM) on cellular cAMP in MRC-5 human lung fibroblasts. After
dissemination, cells were cultured for 24 h in presence of 10 % FCS an
then for by 2 h in HBSS followed by additional 10 min to 4 h (as
indicated) in absence or presence of test drugs. Thereafter, cells were
lysed and cAMP levels determined. Height of columns: a cAMP in
picomole/well, b-d cAMP expressed as percent of the mean levels in
presence of forskolin determined in the respective cell preparation, given
are means+SEM of n≥8. Significance of differences: ***P<0.001 vs
respective control; +++P<0.01 vs resp. Formo and Buta; +P<0.05 vs
forskolin 10 min, ##P<0.01 vs resp. Formo
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fibroblasts showed also the same expression pattern of β-
adrenoceptor subtypes, namely a selective expression of β2-
adrenoceptors, and the same functional response upon β-
adrenoceptor activation (Lamyel et al. 2011), MRC-5 cells
were used in the present study as a cell line which allows
to study physiologically relevant functions in human lung
fibroblasts.
The expression of β2-adrenoceptors in human lung fibro-
blasts appears to be highly regulated at the transcriptional
level. First, the half-life ofβ2-adrenoceptor mRNA is relative-
ly short; β2-adrenoceptor mRNA declined with a half-life of
23 min after addition of actinomycin D. Considering that the
inhibition of RNA synthesis may occur with a certain delay
after addition of actinomycin D to the culture medium, the
half-life of β2-adrenoceptor mRNA may even be shorter.
Therefore, β2-adrenoceptor mRNA levels are expected to
reflect immediately changes in β2-adrenoceptors gene tran-
scription. In fact, significant changes of β2-adrenoceptor
mRNA levels were observed already 20 min after drug expo-
sure (Fig. 1). However, the stability of β2-adrenoceptor
mRNA appears to vary very much in a cell specific manner
and may in addition vary with the culture conditions. Thus, a
relative short half-life of about 45 and 55 min was observed in
DDT1-MF-2 hamster smoothmuscle cells (Collins et al. 1989)
and C6 glioma cells (Hosoda et al. 1995; Danner and Lohse
1997), and in agreement to the present observations, these
short half-lives were not affected by agonist exposure. In
mononuclear leukocytes, a longer half-life of about 2.7 h
was observed which was significantly shorted by agonist
exposure (Tittelbach et al. 1998). Strikingly, Danner and
Lohse (1997) reported that β2-adrenoceptor mRNA in
DDT1-MF-2 hamster smooth muscle cells largely depended
on culture conditions. In cells grown in monolayer culture, the
half-life was about 12 h, but in cell grown in suspension
culture (the conditions also used in the study of Collins et al.
(1989)), it was only 2 h, but under both conditions, it was
shorted by about 50 % in presence of isoproterenol. Thus,
only in cells, in which the stability of β2-adrenoceptor mRNA
is high, an agonist-induced destabilization may occur.
Strikingly, β-adrenoceptor agonist exposure evoked a
marked upregulation of β2-adrenoceptor mRNA expression
which was very rapid in onset, but transient and followed by a
substantial downregulation. Generally, β-adrenoceptors cou-
ple to Gs and mediate via activation of adenylyl cyclase an
increase in cellular cAMP. In the present study, the time-
dependent effects of β-adrenoceptor agonists on β2-
adrenoceptor mRNA expression were mimicked by activation
of adenylyl cyclase by either forskolin or cholera toxin indi-
cating that an increase in cAMP is the crucial signal for these
effects. A similar transient β2-adrenoceptor–cAMP-mediated
upregulation of β2-adrenoceptor gene expression has also
been described by Collins et al. (1989) in DDT1MF-2 hamster
smooth muscle cells, and evidence for a cAMP responsive
element in the β2-adrenoceptor gene was presented (Collins
et al. 1990). Furthermore, a cAMP-mediated reduction in β2-
adrenoceptor mRNAwas also observed in transfected Chinese
hamster fibroblasts expressing human β2-adrenoceptors
(Bouvier et al. 1989).
Human lung fibroblasts express also EP2 prostanoid recep-
tors (Haag et al. 2008b) which are known to couple to
adenylyl cyclase. Short-time exposure to the EP2 receptor
agonist butaprost induced also an upregulation of β2-
adrenoceptor mRNA, which—like the effect of forskolin—
was not additive to the effect of a β-adrenoceptor agonist,
indicating that all three stimuli may act via the same pathway,
activation of adenylyl cyclase.
Only the stimulatory effect of β2-adrenoceptor agonists on
β-adrenoceptor gene expression appears to be the result of a
direct, cAMP-mediated regulation of the β2-adrenoceptor
gene. This is because the stimulatory effect of β2-
adrenoceptor agonists was (1) blocked by actinomycin D
indicating that it was caused by increased transcription and
(2) did not require de novo protein synthesis as it was also
seen in presence of cycloheximide. On the other hand, the
inhibitory effect seen after 4 h agonist exposure was not only
prevented by cycloheximide but converted into marked up-
regulation of β2-adrenoceptor mRNA. This un-masking ac-
tion of cycloheximide indicates that the initial, direct stimula-
tory signal was still operating but was dominantly opposed by
newly synthesized inhibitory factors induced following β2-
adrenoceptor activation via the adenylyl cyclase–cAMP path-
way. Interestingly to note, cycloheximide alone caused a rapid
and marked increase in β2-adrenoceptor mRNA, indicating
that basal β2-adrenoceptor gene expression in human lung
fibroblasts is under inhibitory control of short-living suppres-
sor proteins. Cycloheximide did not affect cellular cAMP
levels, excluding that its effects involve activation of adenylyl
cyclase. The observation that actinomycin D prevented the
cycloheximide-induced increase in β2-adrenoceptor mRNA
supports the conclusion that this effect is caused by an in-
creased transcription rather than the result of a prolonged
stability of the transcript. Whether the β2-adrenoceptor-in-
duced cAMP signal augments the action of these suppressors
or induces additional inhibitory regulators remains unknown
at present, but it will be a challenge for future studies to
identify these regulators which could be potential targets for
drugs aiming to improve and maintain β2-adrenoceptor func-
tion during prolonged agonist exposure.
Although direct activation of adenylyl cyclase by forskolin or
cholera toxin mimicked both the initial stimulatory and delayed
inhibitory effects of β2-adrenoceptor agonists, the non-selective
phosphodiesterase inhibitor IBMX mimicked only the delayed
inhibitory effect. The reason for that appears to be that the
spontaneous activity of adenylyl cyclase is very low and IBMX
did not cause any increase in cellular cAMP levels for up to 1 h.
Even after 4 h exposure, IBMX did not cause a clear, significant
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increase in cellular cAMP. Thus, it is even questionable, whether
the reduction of β2-adrenoceptor mRNA after 4 h exposure to
IBMX was caused by changes in cellular cAMP.
Cellular cAMP signaling can be transmitted either by the
classic effector protein kinase A (PKA) (e.g., Skålhegg and
Taskén 2000) or the alternative cAMP effector Epac (exchange
protein activated by cAMP) of which two variants, Epac1 and
Epac2, have been identified (de Rooij et al. 1998; Kawasakia
et al. 1998). In human lung fibroblasts for example, it has been
shown that PKA and Epac differentially regulate proliferation
and collagen synthesis (Huang et al. 2008; Haag et al. 2008b).
In the present experiments, the selective PKA agonist 6-Bnz-
cAMP (Bos 2006; Holz et al. 2008) mimicked the stimulatory
effect of the β-adrenoceptor agonist, but only in presence of
cycloheximide suggesting that PKA has ability to upregulate
directly β-adrenoceptor gene expression, but this action is
opposed by PKA-induced inhibitory regulators. On the other
hand, Epac appears not to play a major role in the regulation of
β2-adrenoceptor expression as 8-CPT-2′–O-Me-cAMP, a se-
lective Epac activator (Bos 2006; Holz et al. 2008) did not
show any significant effect, neither in absence nor presence of
cycloheximide. It should be mentioned that in previous exper-
iments using the same cells and the same concentrations of 6-
Bnz-cAMP and 8-CPT-2′–O-Me-cAMP, these agonists medi-
ated a marked and selective inhibition of either the synthesis of
collagen or cell proliferation, respectively (Haag et al. 2008b).
In conclusion, expression ofβ2-adrenoceptors in human lung
fibroblasts is highly regulated at transcriptional level, suggesting
that β2-adrenoceptor expression may rapidly respond to physi-
ological or pathological changes as well as pharmacological
interventions. The β2-adrenoceptor gene appears to be under
strong inhibitory control of short-living, not yet identified sup-
pressor proteins. Although both, the time-dependent up- and
downregulation of the β2-adrenoceptor gene expression by β2-
adrenoceptor activation appears to be mediated via adenylyl
cyclase–cAMP signaling, only the stimulatory effect appears
to be a direct action on the β2-adrenoceptor gene.
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